MARIPOSA: phase 3 study of first-line amivantamab + lazertinib versus osimertinib in EGFR-mutant non-small-cell lung cancer

Third-generation EGFR tyrosine kinase inhibitors (TKIs), such as osimertinib, have demonstrated efficacy in patients with -mutant non-small-cell lung cancer; however, almost all patients will eventually relapse. Amivantamab is an EGFR-MET bispecific antibody with immune cell-directing activity that...

Full description

Saved in:
Bibliographic Details
Published in:Future oncology (London, England) Vol. 18; no. 6; p. 639
Main Authors: Cho, Byoung Chul, Felip, Enriqueta, Hayashi, Hidetoshi, Thomas, Michael, Lu, Shun, Besse, Benjamin, Sun, Tao, Martinez, Melissa, Sethi, Seema N, Shreeve, S Martin, Spira, Alexander I
Format: Journal Article
Language:English
Published: England 01.02.2022
Subjects:
Acrylamides - adverse effects
Acrylamides - therapeutic use
Adolescent
Adult
Aniline Compounds - adverse effects
Aniline Compounds - therapeutic use
Antibodies, Bispecific - adverse effects
Antibodies, Bispecific - therapeutic use
Antineoplastic Agents, Immunological - adverse effects
Antineoplastic Agents, Immunological - therapeutic use
Antineoplastic Combined Chemotherapy Protocols - adverse effects
Antineoplastic Combined Chemotherapy Protocols - therapeutic use
Carcinoma, Non-Small-Cell Lung - drug therapy
Carcinoma, Non-Small-Cell Lung - genetics
Carcinoma, Non-Small-Cell Lung - pathology
Clinical Trials, Phase III as Topic
ErbB Receptors - antagonists & inhibitors
ErbB Receptors - genetics
Humans
Lung Neoplasms - drug therapy
Lung Neoplasms - genetics
Lung Neoplasms - pathology
Morpholines - adverse effects
Morpholines - therapeutic use
Multicenter Studies as Topic
Mutation
Neoplasm Metastasis
Protein Kinase Inhibitors - adverse effects
Protein Kinase Inhibitors - therapeutic use
Pyrazoles - adverse effects
Pyrazoles - therapeutic use
Pyrimidines - adverse effects
Pyrimidines - therapeutic use
Randomized Controlled Trials as Topic
Research Design
Young Adult
amivantamab
tyrosine kinase inhibitors
EGFR mutations
lazertinib
non-small-cell lung cancer
ISSN:1744-8301, 1744-8301
Online Access:Get more information
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Third-generation EGFR tyrosine kinase inhibitors (TKIs), such as osimertinib, have demonstrated efficacy in patients with -mutant non-small-cell lung cancer; however, almost all patients will eventually relapse. Amivantamab is an EGFR-MET bispecific antibody with immune cell-directing activity that targets activating and resistance mutations and mutations and amplifications. In the ongoing CHRYSALIS study (NCT02609776), amivantamab in combination with lazertinib, a potent, brain-penetrant third-generation EGFR TKI, demonstrated antitumor activity in the treatment-naive and osimertinib-relapsed setting. Here the authors present the methodology for the MARIPOSA study (NCT04487080), a phase 3, multicenter, randomized study designed to compare the efficacy and safety of amivantamab and lazertinib combination therapy versus single-agent osimertinib as first-line treatment for -mutant non-small-cell lung cancer.
Bibliography:ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Undefined-1
ObjectType-Feature-3
content type line 23
ISSN:1744-8301
1744-8301
DOI:10.2217/fon-2021-0923